ライフサイエンスコーパス: cysteamine

1 iers such as SIGCAFKILGY(-cysteamine) [SIGC(-cysteamine)].

2 to produce pantothenic acid (vitamin B5) and cysteamine.

3 pionic acid, 4-pyridinylethanemercaptan, and cysteamine.

4 increased the production of hypotaurine from cysteamine.

5 o the enzymes cysteine dioxygenase (CDO) and cysteamine (2-aminoethanethiol) dioxygenase (ADO).

6 -cysteine with isosteric substrate analogues cysteamine, 3-mercaptopropionic acid, and propane thiol

7 Fresh cysteamine (600 mg/kg) was added to drinking water daily

8 pered our understanding of the metabolism of cysteamine, a product of the constitutive degradation of

9 Two types of cationic AuNPs, cysteamine and CTAB capped, were compared to achieve max

10 Cysteamine and cystamine also augmented basal intracellu

11 ioprotectants including human serum albumin, cysteamine and glycerol were evaluated.

12 However, experimental studies with the thiol cysteamine and its disulfide cystamine have demonstrated

13 e or withanolide A, was highly reactive with cysteamine and rapidly succumbed to irreversible nucleop

14 therefore studied the actions of cystamine, cysteamine and several reference thiol agents as cytopro

15 ell-known radioprotective agents L-cysteine, cysteamine, and 2-[(aminopropyl)amino]ethanethiol (WR-10

16 Intracellular thiols (e.g., cysteine, cysteamine, and glutathione) can trigger the release of

17 enal transplantation, administration of oral cysteamine, and time and cause of death.

18 t assay using 14C-(C-1)-labeled L-serine and cysteamine as substrates, counting the thialysine produc

19 Patients received oral cysteamine bitartrate (60 mg/kg per day) and N-acetylcys

20 ndings suggest that combination therapy with cysteamine bitartrate and N-acetylcysteine is associated

21 aimed to assess whether combination of oral cysteamine bitartrate and N-acetylcysteine is beneficial

22 olled trial to determine whether 52 weeks of cysteamine bitartrate delayed release (CBDR) reduces the

23 two patients, which disappeared when liquid cysteamine bitartrate was replaced with capsules.

24 s, we evaluated the antifibrotic efficacy of cysteamine bitartrate, an antioxidant therapy for patien

25 the sensitive voltammetric determination of cysteamine (CA), nicotinamide adenine dinucleotide (NADH

26 such as acetone, acetaldehyde, isoprene, or cysteamine can be detected in the breath gas with SPI, R

27 The large difference in the yields of cysteamine can be used to explain the drugs' different t

28 sulfonic acid, mercapto-propionyglycine, and cysteamine can directly sequester aldehydes.

29 The sensor relies on cysteamine capped gold nanoparticles (N-AuNPs) covalentl

30 protection using a recently developed Trolox-cysteamine cocktail.

31 of autophagy activators involving fatty acid cysteamine conjugates.

32 Lipophilic thiols such as mercaptoethanol or cysteamine could partially reverse the CCl4-induced calc

33 By functionalizing cysteamine (CS)-stabilized gold nanoparticles (CS-AuNPs)

34 , separation-free and selective detection of cysteamine (CSH).

35 Copper Cysteamine (Cu-Cy) is a new photosensitizer and a novel

36 yer principle by modifying Au electrode with cysteamine (Cys) and immobilization of ferrocene cored p

37 lized on the Au/SPE previously aminated with cysteamine (Cys) by self-assembling monolayer technique.

38 In electrode fabrication cysteamine (Cys) was the first agent covalently linked o

39 nic acid (cysteine without the amino group), cysteamine (cysteine without the carboxylic acid), or me

40 The reaction was highly specific for cysteamine; cysteine was not oxidized by the enzyme, and

41 Decrease of lysosomal cystine levels by cysteamine did not rescue mTORC1 activation in these cel

42 raldehyde crosslinking and functionalized by cysteamine dihydrochloride.

43 combinant protein, ADO exhibited significant cysteamine dioxygenase activity in vitro.

44 ggest that ADO is responsible for endogenous cysteamine dioxygenase activity.

45 ly of enzymes includes cysteine dioxygenase, cysteamine dioxygenase, mercaptosuccinate dioxygenase, a

46 he protein, relatively little is known about cysteamine dioxygenase.

47 ned carbon chain and lacks a carboxyl group, cysteamine displays a catalytic efficiency (kcat/Km) wit

48 However, because cysteamine does not correct all complications of cystino

49 modified with a self-assembled monolayer of cysteamine followed by cross-linking with glutaraldehyde

50 ations and deaths than patients who received cysteamine for fewer than 8 years.

51 to be ineffective at zinc ejection, although cysteamine formed a transient complex with the zinc fing

52 d that the steady state percentage yields of cysteamine from cystamine and pantethine during the tran

53 vate, homocysteine (from cystathionine), and cysteamine (from S-aminoethyl-L-cysteine).

54 In the case of the bacterial member ELIC, a cysteamine-gated channel from Erwinia chrisanthemi, a st

55 abeled diketide-SNAC 2 and N-[1-(14)C-acetyl]cysteamine gave a k(exch) of 0.15 +/- 0.06 min(-)(1), wi

56 We report herein the use of cysteamine-graphene oxide modified gold microelectrode a

57 amine) specifically and efficiently leads to cysteamine (half-cystamine) modification of a single sit

58 ted the extracellular levels of free reduced cysteamine, homocysteine, and cysteine from OHSCs within

59 Concentrations of cysteamine, homocysteine, and cysteine in the extracellu

60 Cysteamine hydrochloride (Cyst), 3-Mercaptopropionic aci

61 d directly using a specific radiolabel, [14C]cysteamine hydrochloride.

62 n situ quantitative estimation of endogenous cysteamine in brain tissue.

63 sed on layer-by-layer assembly was formed by cysteamine in combination with a fourth-generation poly(

64 relies upon the finding that hCBS will take cysteamine in place of L-homocysteine, thereby producing

65 Based on the formation rate of cysteamine in the OHSCs, we obtained the overall apparen

66 of N-acetylating a model compound containing cysteamine in the presence of acetyl-CoA, consistent wit

67 eptide, and subsequent Michael addition with cysteamine increased masses by the predicated 77 and 154

68 Cysteamine-induced ulceration in EGF(-/-) mice was used

69 In fact, cysteamine is shown to be a potent activator of the enzy

70 bilayer and semi circled DDA on the MPA and cysteamine layers were confirmed by the increased redox

71 Plasma cysteamine levels showed diurnal variation, with peak le

72 cystamine also augmented basal intracellular cysteamine levels.

73 opamine by the RNA aptamer, immobilized at a cysteamine-modified Au electrode, and further electroche

74 interactions between the positively charged cysteamine-modified electrode and the negatively charged

75 ence of 1,4-phenylene diisothiocyanate, on a cysteamine-modified gold electrode.

76 be performed by the RNA aptamer tethered to cysteamine-modified gold electrodes via the alkanethiol

77 gold electrodes via carbodiimide coupling to cysteamine-modified gold electrodes.

78 al bilayers was promoted by anchoring of the cysteamine moiety.

79 , heme oxygenase-1, neutrophil infiltration, cysteamine, mucin, hydrogen sulfide, ghrelin, adiponecti

80 e chain elongation intermediates as N-acetyl cysteamine (NAC) thioesters and have used them as substr

81 e synthesis of taurine, the final product of cysteamine oxidation and the second most abundant amino

82 rophage cultures revealed that cystamine and cysteamine possess significant antiviral properties at n

83 with 70 mol % mercaptopropanol and 30 mol % cysteamine/propanedithiol to facilitate membrane fusion

84 Furthermore, treatment with cysteamine reduced alpha-smooth muscle actin-positive in

85 ults, treatment of cultured macrophages with cysteamine reduced cellular generation of reactive oxyge

86 rs (e.g., DMSO, glycerol, and cationic thiol cysteamine) reduces the incidence of instability after i

87 m and cystamine, diethyl dithiocarbamate and cysteamine, respectively, were found to be ineffective a

88 erestingly, exposure of cells to cysteine or cysteamine resulted in elevated intracellular hypotaurin

89 cystinotic cells' cystine content by use of cysteamine results in normalization of the apoptotic rat

90 unosensor for the detection of MDM2 based on cysteamine self assembled monolayers on a clean polycrys

91 using peptide carriers such as SIGCAFKILGY(-cysteamine) [SIGC(-cysteamine)].

92 specificity for bioorthgonal short N-acetyl cysteamine (SNAc) donors.

93 ite-directed mutagenesis indicate that SIGC(-cysteamine) specifically and efficiently leads to cystea

94 od an aptamer was used to aggregate cationic cysteamine-stabilized CdTe/ZnS core/shell quantum dots,

95 Other antioxidants, approved for human use (cysteamine, succimer, dimercaprol), were not efficacious

96 utants in the presence of a concentration of cysteamine that elicits an intracluster open probability

97 of apoptosis that could be ameliorated with cysteamine, the human cystine depleting therapy.

98 Oral cysteamine therapy delays disease progression by reducin

99 investigation into the potential benefit of cysteamine therapy in the treatment of CKD.

100 tment increased, and it decreased as time on cysteamine therapy increased.

101 In a study of renal ischemia reperfusion, cysteamine therapy initiated 10 days after injury and co

102 Long-term oral cysteamine therapy mitigates these effects.

103 de that serves as a chemical intermediate in cysteamine therapy of cystinosis, and PQLC2 gene silenci

104 adulthood and the effects of long-term oral cysteamine therapy on its nonrenal complications have no

105 who received long-term (> or =8 years) oral cysteamine therapy were taller and heavier, had a renal

106 ucidation of PQLC2 function may help improve cysteamine therapy.

107 eaction of some of its epoxide moieties with cysteamine to afford a monolith rich in surface thiol gr

108 hrough reaction of its epoxide moieties with cysteamine to afford a monolith rich in surface thiol gr

109 were synthesized by first covalently linking cysteamine to docosahexaenoic acid.

110 In cysteamine-treated mice, fibrosis severity decreased sig

111 displayed more severe lesions in response to cysteamine treatment compared with wild-type counterpart

112 othyroidism, and death increased as time off cysteamine treatment increased, and it decreased as time

113 viously unrecognized antifibrotic actions of cysteamine via TGF-beta-independent mechanisms that incl

114 Vancomycin/synthetic acyl-N-acetyl cysteamine was not expected to be able to serve as a sur

115 phosphopantetheine, pantetheine, and finally cysteamine was observed with ThnR, ThnH, and ThnT, respe

116 onyl-S-pantetheine or L-threonyl-S-(N-acetyl)cysteamine was used as a small-molecule thioester analog

117 st successful of these biomimetic catalysts (cysteamine) was used to encapsulate firefly luciferase,

118 athione, and the simplest stable aminothiol, cysteamine, we enabled the nanoparticles to exhibit not

119 2+/-0.2 mM for L-serine and 5.6+/-2.2 mM for cysteamine, with kcat = 1.3+/-0.1s(-1) for the formation

120 2.2+/-0.5 mM for L-serine and 6.6+/-2.2 for cysteamine, with kcat = 2.5+/-0.4 s(-1).